More research is needed to better understand the consequences of holding or discontinuing ICI treatments due to immune-mediated severe adverse events in uveal melanoma, as this may influence further anti-PD1 + anti-CTLA4 drug development, as well as clinicians’ readiness to re-institute ICI after an adverse event. The gene discussed is CTLA4; the disease is uveal melanoma.